Book

Description

Scientists realized this fact finally towards the end of 20th century and thus cancer selective targeting became one of the most important goals. Most conventional low molecular weight anticancer drugs have inherent character to traverse in and out of blood vessels freely, unless the drug is linked with a tumor specific molecular ligand having high binding constant. For instance low molecular weight drugs injected intramuscularly reach to distant site of the body in ten minutes. Consequently, their undesirable indiscriminatory distribution in normal tissues causes severe systemic side-effects in case of anticancer agents. The polymer therapeutics or nanomedicines are designed to improve drug performance by utilizing pathophysiological uniqueness of solid tumor, of which conventional low molecular weight drugs are incapable.